GlassScriptPhysician profile
Elizabeth Mirro
NPI 1396850061
$5,354.54
in general payments reported to CMS, 2019-2025
39 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $675 · 2021: $1,021 · 2022: $1,022 · 2023: $639 · 2024: $762 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $809.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $613.60 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $528.25 | 2021-2025 | |
| Pfizer INC. | $465.07 | 2019-2025 | |
| Lilly USA, LLC | $394.55 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $338.65 | 2019-2025 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $261.17 | 2019-2022 | |
| Amarin Pharma, INC. | $233.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $184.68 | 2019-2023 | Dificid |
| Sumitomo Pharma America, INC. | $154.71 | 2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $142.10 | 2019-2023 | Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.58 | 2019-2024 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $123.95 | 2019-2024 | |
| Exact Sciences Corporation | $121.39 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $115.44 | 2022-2024 | Xarelto |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $62.20 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.63 | 2021-2023 | |
| Esperion Therapeutics, INC. | $51.35 | 2020-2023 | Nexletol |
| Seqirus USA INC | $51.23 | 2019-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Supernus Pharmaceuticals, INC. | $44.50 | 2019-2021 | |
| Genentech USA, INC. | $43.73 | 2020-2021 | |
| Ardelyx, INC. | $43.54 | 2023-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $39.42 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $34.90 | 2025 | Inspire |
| Phadia US INC. | $27.40 | 2021-2024 | Immunocap |
| Novavax INC | $26.40 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Dynavax Technologies Corporation | $25.23 | 2025 | Heplisav-B |
| Abbott Laboratories | $24.48 | 2022 | |
| Corcept Therapeutics | $24.00 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $22.90 | 2025 | Keveyis |
| Daiichi Sankyo INC. | $22.85 | 2019 | |
| Dexcom, INC. | $22.58 | 2022 | |
| Ibsa Pharma INC. | $22.01 | 2022 | |
| Bausch Health US, LLC | $20.38 | 2022 | |
| Teleflex LLC | $20.18 | 2022 | |
| Philips North America LLC | $16.66 | 2024 | (Ck7) Extended Holter |
| Hikma Pharmaceuticals USA | $16.56 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.48 | 2024 | Ultomiris |
| Bardy Diagnostics, INC. | $13.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mirro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.